Straits Research released its highly anticipated report, “Global Joint Reconstruction Devices Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 29.48 billion in 2025 and is anticipated to grow till USD 42.10 billion by 2034, growing at a CAGR of 4.08% from 2026-2034.
The joint reconstruction devices market is increasingly driven by the rapid integration of AI-assisted surgical platforms that refine implant positioning, guide alignment decisions, and support surgeons with real-time biomechanical insights during hip, knee, and shoulder procedures. Recent approvals of AI-enabled navigation modules and automated impaction systems have strengthened clinical confidence in technology-enhanced workflows, prompting hospitals to upgrade operating rooms and adopt implants compatible with digital planning tools. This shift toward data-supported surgical precision expands the appeal of advanced reconstruction systems among high-volume orthopedic centers. Despite this momentum, the market continues to face restraints stemming from complex and inconsistent reimbursement pathways that slow the adoption of newer implant types. Public health systems in several regions apply stringent coverage criteria for partial replacements, resurfacing implants, and select revision procedures, resulting in delayed approvals and extended patient wait times. These administrative bottlenecks influence both provider scheduling and patient willingness to undergo reconstruction, reducing overall market penetration. At the same time, the market is positioned for growth through the expanding use of remote rehabilitation ecosystems that combine wearable motion sensors with digital platforms to monitor gait, joint loading, and recovery milestones after surgery. These systems reduce the burden of in-person follow-ups, support individualized rehabilitation plans, and enable clinicians to intervene early when progress declines. The integration of implant performance data with remote monitoring applications opens new pathways for value-added care models, allowing manufacturers to pair reconstruction devices with post-surgical optimization tools that improve long-term functional outcomes and broaden access to structured recovery programs across diverse patient groups.
October 2025: DePuy Synthes (Johnson & Johnson MedTech) launched the INHANCE INTACT total shoulder replacement system in the U.S., featuring a tissue-sparing, subscapularis-sparing approach that preserved the subscapularis muscle and allowed day-one post-operative mobility.